Effect of chemical modification strategy on the characteristics of copper-67-labeled immunoconjugates .1. Immunoreactivity

被引:3
作者
Bhalgat, MK
Roberts, JC
MercerSmith, JA
Vessella, RL
Lavallee, DK
机构
[1] UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112
[2] LOS ALAMOS NATL LAB,MED RADIOISOTOPES RES PROGRAM,LOS ALAMOS,NM
[3] UNIV WASHINGTON,DEPT UROL,SEATTLE,WA 98195
[4] CUNY HUNTER COLL,NEW YORK,NY 10021
基金
美国国家卫生研究院;
关键词
antibody delivery; antibody fragments; copper-67; F(ab')(2); immunoreactivity; porphyrin chelators; renal cell carcinoma; starburst dendrimers; targeting;
D O I
10.3109/10717549709033181
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The synthetic porphyrins N-benzyl-5,10,15,20-tetrakis(4-carboxyphenyl)porphine (N-bzHTCPP) and N-4-nitrobenzyl-5-(4-carboxyphenyl)-10,15,20-tris(4-sulfophenyl)porphine (NbzHCS(3)P) represent excellent radiocopper chelating agents that may find utility in antibody-mediated diagnosis and/or therapy. Detailed analyses were performed to explore the effect of the chemical modification strategy on the characteristics of immunoconjugates prepared from the anti-renal cell carcinoma monoclonal antibody A6H and N-bzHCS(3)P. The parameters included in the study were antibody type [intact A6H and two of its fragments, half A6H and A6H-F(ab')(2)], chemical linkage type and site, the presence or absence of intermediate linker molecules, and the nature of the chemical modification steps employed. The immunoconjugate synthesized by directly coupling N-bzHCS(3)P to whole antibody retained 75-85% of the immunoreactivity of the unmodified antibody. In general, however immunoconjugates prepared using the fragments or the intermediate linkers lacked immunoreactivity, This deficiency appeared to be a function of the multistep processes employed and not a function of the tinker molecule. The results emphasize the critical importance of the type and number of antibody modification steps and the caution that must be exercised in the design of immunoconjugates for drug delivery purposes.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 56 条
[51]  
VESSELLA RL, 1985, CANCER RES, V45, P6131
[52]  
VESSELLA RL, 1988, ANTIBODY MEDIATED DE, P245
[53]   RADIONUCLIDE SELECTION AND MODEL ABSORBED DOSE CALCULATIONS FOR RADIOLABELED TUMOR ASSOCIATED ANTIBODIES [J].
WESSELS, BW ;
ROGUS, RD .
MEDICAL PHYSICS, 1984, 11 (05) :638-645
[54]   DENDRIMER-BASED METAL-CHELATES - A NEW CLASS OF MAGNETIC-RESONANCE-IMAGING CONTRAST AGENTS [J].
WIENER, EC ;
BRECHBIEL, MW ;
BROTHERS, H ;
MAGIN, RL ;
GANSOW, OA ;
TOMALIA, DA ;
LAUTERBUR, PC .
MAGNETIC RESONANCE IN MEDICINE, 1994, 31 (01) :1-8
[55]   MONOCLONAL-ANTIBODY FAB' FRAGMENT CROSS-LINKING USING EQUILIBRIUM TRANSFER ALKYLATION REAGENTS - A STRATEGY FOR SITE-SPECIFIC CONJUGATION OF DIAGNOSTIC AND THERAPEUTIC AGENTS WITH F(AB')(2) FRAGMENTS [J].
WILBUR, DS ;
STRAY, JE ;
HAMLIN, DK ;
CURTIS, DK ;
VESSELLA, RL .
BIOCONJUGATE CHEMISTRY, 1994, 5 (03) :220-235
[56]   PREPARATION AND EVALUATION OF PARA-[AT-211]ASTATOBENZOYL LABELED ANTIRENAL CELL-CARCINOMA ANTIBODY A6H F(AB')2 - IN-VIVO DISTRIBUTION COMPARISON WITH PARA-[I-125]IODOBENZOYL LABELED A6H F(AB')2 [J].
WILBUR, DS ;
VESSELLA, RL ;
STRAY, JE ;
GOFFE, DK ;
BLOUKE, KA ;
ATCHER, RW .
NUCLEAR MEDICINE AND BIOLOGY, 1993, 20 (08) :917-927